Novel CD4/CD8 design delivers most comprehensive evaluation of patients' immune response to tuberculosis infection
GERMANTOWN, Maryland and HILDEN, Germany, October 5, 2017 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available on October 9, 2017 for diagnostic use following U.S. Food and Drug Administration approval in June.
QFT-Plus advances the science of TB testing with innovative antigens that measure the cell-mediated immune response to tuberculosis infection from both CD4+ and CD8+ T cells - providing a broader assessment of TB infection. CD8+ T cells have been shown to play an important role in Mycobacterium tuberculosis immunity.
Click here for the full press release
http://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-05-QFT-Plus-Launch-US?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49-2103-29-11711
Public Relations
Dr. Thomas Theuringer
e-mail: pr@QIAGEN.com
+49-2103-29-11826
GERMANTOWN, Maryland and HILDEN, Germany, October 5, 2017 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available on October 9, 2017 for diagnostic use following U.S. Food and Drug Administration approval in June.
QFT-Plus advances the science of TB testing with innovative antigens that measure the cell-mediated immune response to tuberculosis infection from both CD4+ and CD8+ T cells - providing a broader assessment of TB infection. CD8+ T cells have been shown to play an important role in Mycobacterium tuberculosis immunity.
Click here for the full press release
http://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-05-QFT-Plus-Launch-US?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49-2103-29-11711
Public Relations
Dr. Thomas Theuringer
e-mail: pr@QIAGEN.com
+49-2103-29-11826
